ghk cu 3 times a week GHK-Cu isn't about instant change. It's about cellular A Dermatologist's Take on the

March 2017

Dihexa vs Cerebrolysin Dihexa and Cerebrolysin both target cognitive enhancement and neuroprotection, but they occupy fundamentally different positions on the evidence spectrum

Use with caution in patients with Lebers disease (hereditary optic nerve atrophy)

efficacy goal was not met Claim 300500 mcg per day Published human support No controlled human SubQ study Community support Commonly reported How it should be described Community research amount Claim Start at 300 mcg and increase after four weeks Published human support No Community support Commonly reported How it should be described Anecdotal step-up model Claim 8- or 16-week SubQ cycle Published human support No Community support Commonly reported How it should be described Community timeline only Claim Use beyond 24 weeks Published human support No Community support Scattered reports How it should be described Unsupported by published long-term evidence AOD-9604 is not an FDA-approved drug

Athira Pharma's fosgonimeton (ATH-1017) targets the same HGF/c-Met program but is structurally distinct (sources conflict on whether it is a prodrug of Dihexa or a separate molecule)

PubMed laboratory research record [PMID: 18416133] PubMed record related to this compound for laboratory literature review